Subclinical cardiovascular disease

Subclinical cardiovascular disease has no effect on cerebral blood flow in humans.

“but not with changes in total brain tissue volume or cerebral blood flow.”

Human trialin hypertensive adultsn = 639

Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial

The journals of gerontology. Series A, Biological sciences and medical sciences·8 Jan 2025

Subclinical cardiovascular disease increases white matter lesions in humans.

“Elevated levels of both biomarkers were also associated with a faster progression in white matter lesions”

Human trialin hypertensive adultsn = 639

Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial

The journals of gerontology. Series A, Biological sciences and medical sciences·8 Jan 2025

Subclinical cardiovascular disease impairs global cognitive function in humans (annual decline rate of 0.033 (95% CI: 0.024-0.041) in z-score).

“The group with elevated levels of both cardiac biomarkers showed the fastest decline, with a larger annual decline rate of 0.033 (95% CI: 0.024-0.041) in the z-score of global cognitive function”

Human trialin hypertensive adultsn = 2,733

Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial

The journals of gerontology. Series A, Biological sciences and medical sciences·8 Jan 2025